Vaniqa, a hair growth retardant, is indicated to reduce unwanted facial hair in women. Vaniqa (eflornithine HCl; Allergan) Cream 13.9% is currently unavailable due to a shortage of active ingredient, ...

CARLSBAD, Calif.--(BUSINESS WIRE)--June 28, 2004--SkinMedica(R) Inc., a specialty pharmaceutical company developing and commercializing dermatology products, announced today that it is the winning ...

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa ® and ...

Eflornithine 13.9% (Vaniqa) cream is FDA-approved to reduce growth of unwanted facial hair in women. A randomized trial of 33 women aged 22-65 years evaluated the efficacy of eflornithine use in ...

Please provide your email address to receive an email when new articles are posted on . Cipher Pharmaceuticals announced the Canadian market launch of Vaniqa, which was recently licensed from Almirall ...

CARLSBAD — SkinMedica, a Carlsbad-based specialtypharmaceutical company, has paid $36.6 million to prove that it cando a better job of selling a skin-care product than its previousowner. Privately ...

HOUSTON RediClinic, which operates more than 20 clinics in H-E-B grocery stores in Houston and Austin, has expanded its menu of services with the addition of prescription medications Vaniqa and Lustra ...

Please provide your email address to receive an email when new articles are posted on . Cipher Pharmaceuticals announced it has acquired the Canadian commercialization rights to Vaniqa and Actikerall ...

Cipher Pharmaceuticals Inc, a rapidly growing specialty pharmaceutical dermatology company, has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa and ...

VaniqaT is a prescription drug which was approved by the FDA in the United States on July 31, 2000 for treating excessive facial hair in women, which is often part of hirsutism. It may be a welcome ...

A problem affecting millions of women is excess facial hair. Removing it can be costly, time-consuming and painful. Now, for the first time, the Food and Drug Administration has approved a treatment ...